Tygacil is a drug owned by Pf Prism Cv. It is protected by 8 US drug patents filed from 2013 to 2020. Out of these, 6 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 08, 2030. Details of Tygacil's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tygacil's patents.

Latest Legal Activities on Tygacil's Patents

Given below is the list of recent legal activities going on the following patents of Tygacil.

Activity	Date	Patent Number
Critical Events for all Patents
Payment of Maintenance Fee, 12th Year, Large Entity	11 Jul, 2024	US8372995 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity	10 Aug, 2023	US10588975
Payment of Maintenance Fee, 8th Year, Large Entity	13 Jul, 2023	US9254328
Payment of Maintenance Fee, 8th Year, Large Entity	10 Aug, 2022	US8975242 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	13 Jul, 2022	US7879828 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity	28 Sep, 2020	US9694078
Payment of Maintenance Fee, 8th Year, Large Entity	14 Jul, 2020	US8372995 (Litigated)
Recordation of Patent Grant Mailed Critical	17 Mar, 2020	US10588975
Patent Issue Date Used in PTA Calculation Critical	17 Mar, 2020	US10588975
Email Notification Critical	27 Feb, 2020	US10588975

While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Tygacil and ongoing litigations to help you estimate the early arrival of Tygacil generic.

Tygacil's Litigations

Tygacil been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 08, 2014, against patent number US7879828. The petitioner Initiative for Responsibility in Drug Pricing LLC, challenged the validity of this patent, with Wyeth LLC as the respondent. Click below to track the latest information on how companies are challenging Tygacil's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
Live updates
US7879828	March, 2015	Terminated-Denied (16 Sep, 2015)	Wyeth LLC	Apotex Inc.
US7879828	November, 2013	FWD Entered (20 Apr, 2015)	Wyeth LLC	Apotex Inc.
US7879828	August, 2014	Terminated-Denied (13 Feb, 2015)	Wyeth LLC	Initiative for Responsibility in Drug Pricing LLC

FDA has granted some exclusivities to Tygacil. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Tygacil, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Tygacil.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

Several oppositions have been filed on Tygacil's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Tygacil's generic, the next section provides detailed information on ongoing and past EP oppositions related to Tygacil patents.

Tygacil's Oppositions Filed in EPO

Tygacil has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 24, 2014, by Galenicum Health S.L.. This opposition was filed on patent number EP06760544A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status
Live updates
EP06737947A	Jun, 2014	Hollatz, Christian	Patent maintained as amended
EP06737947A	Jun, 2014	Hollatz, Christian	Patent maintained as amended
EP06737947A	Jun, 2014	PENTAFARMA S.A.	Patent maintained as amended
EP06737947A	Jun, 2014	df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB	Patent maintained as amended
EP06760544A	Jan, 2014	Taylor Wessing LLP	Revoked
EP06760544A	Jan, 2014	Galenicum Health S.L.	Revoked

US patents provide insights into the exclusivity only within the United States, but Tygacil is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tygacil's family patents as well as insights into ongoing legal events on those patents.

Tygacil's Family Patents

Tygacil has patent protection in a total of 29 countries. It's US patent count contributes only to 16.7% of its total global patent coverage. 10 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Tygacil.

Full family tree

Generic Launch

About Tygacil

Tygacil is a drug owned by Pf Prism Cv. It is used for treating bacterial infections. Tygacil uses Tigecycline as an active ingredient. Tygacil was launched by Pf Prism Cv in 2005.